title: Feasibility of Repairing Defects Followed by Treatment with Pulmonary Hypertension-specific Drugs (Repair and Treat) in Patients with Pulmonary Hypertension Associated with Atrial Septal Defect: Study Protocol for Interventional Trial.
abstract: A treatment strategy for patients with pulmonary hypertension (PH) and atrial septal defect (ASD) remains unclear. This study was designed to evaluate the effects of initial repair of ASD followed by treatment with PH-specific drugs in patients with PH and ASD. Eligible patients receive transcatheter ASD closure followed by treatment with bosentan and sildenafil. Right heart catheterization is performed at baseline and at 12, 24 and 48 weeks. The primary endpoint is change in pulmonary artery pressure and pulmonary vascular resistance from baseline to follow-up. This study should provide valuable information to establish a therapeutic strategy for PH and ASD.
authors: Department of Cardiovascular Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Science, Okayama 700-8558, Japan.akagi-s@cc.okayama-u.ac.jp.
authors: Satoshi
authors: S
authors: Akagi
authors: Kazufumi
authors: K
authors: Nakamura
authors: Teiji
authors: T
authors: Akagi
authors: Koji
authors: K
authors: Nakagawa
authors: Yoichi
authors: Y
authors: Takaya
authors: Toshihiro
authors: T
authors: Sarashina
authors: Kentaro
authors: K
authors: Ejiri
authors: Hiroshi
authors: H
authors: Ito
mesh_terms: D000959:Antihypertensive Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D000077300:Bosentan; D002985:Clinical Protocols; D004334:Drug Administration Schedule; D005240:Feasibility Studies; D006344:Heart Septal Defects, Atrial / Q000150:complications*; D006801:Humans; D006976:Hypertension, Pulmonary / Q000209:etiology* / Q000601:surgery*; D011446:Prospective Studies; D000068677:Sildenafil Citrate / Q000008:administration & dosage / Q000627:therapeutic use; D013449:Sulfonamides / Q000008:administration & dosage / Q000627:therapeutic use
chemical_list: D000959:Antihypertensive Agents; D013449:Sulfonamides; D000068677:Sildenafil Citrate; D000077300:Bosentan